Glucagon RTU
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hyperinsulinemic Hypoglycemia
Conditions
Hyperinsulinemic Hypoglycemia
Trial Timeline
May 10, 2019 → Feb 26, 2020
NCT ID
NCT03770637About Glucagon RTU
Glucagon RTU is a phase 2 stage product being developed by Xeris Pharmaceuticals for Hyperinsulinemic Hypoglycemia. The current trial status is completed. This product is registered under clinical trial identifier NCT03770637. Target conditions include Hyperinsulinemic Hypoglycemia.
Hype Score Breakdown
Clinical
12
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03770637 | Phase 2 | Completed |
Competing Products
2 competing products in Hyperinsulinemic Hypoglycemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Pasireotide | Novartis | Phase 1 | 29 |
| Dasiglucagon + Placebo | Zealand Pharma | Phase 2 | 32 |